v3.26.1
Revenue and government financing for research expenditures - Additional Information (Details)
€ in Thousands, $ in Thousands
1 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
EUR (€)
Dec. 19, 2023
EUR (€)
option
Jul. 11, 2023
EUR (€)
Apr. 03, 2023
USD ($)
Apr. 03, 2023
EUR (€)
Jan. 25, 2023
USD ($)
Jan. 25, 2023
EUR (€)
Aug. 02, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2022
EUR (€)
Jan. 05, 2021
EUR (€)
Dec. 07, 2020
USD ($)
Jun. 30, 2023
EUR (€)
Mar. 31, 2023
EUR (€)
option
Aug. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Oct. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Jan. 31, 2019
USD ($)
Apr. 30, 2024
EUR (€)
Jun. 30, 2022
EUR (€)
Dec. 31, 2025
USD ($)
option
Dec. 31, 2025
EUR (€)
option
Dec. 31, 2024
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2019
USD ($)
Oct. 09, 2024
Jul. 25, 2024
Dec. 31, 2019
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Revenue from collaboration and licensing agreements                                               € 2,787   € 12,622 € 51,901        
2015 monalizumab agreement, with AstraZeneca                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Revenue from collaboration and licensing agreements                 $ 14,000 € 13,400                                          
Initial payment | $                                                       $ 250,000      
Exercise of option | $                                       $ 100,000                      
Revenue from favorable cumulative adjustment                                                             € 38,300
Milestone payment received                 50,000 47,700   $ 50,000       $ 50,000   $ 50,000                          
2015 monalizumab agreement, with AstraZeneca | Collaboration liabilities                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Additions                 $ 36,000 € 34,300                           141   401 (173)        
IPH5201 agreement, with AstraZeneca                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Revenue from collaboration and licensing agreements                                               0   0 0        
Milestone payment received | $               $ 5,000             $ 5,000       $ 5,000                        
Other revenue, reinvoicing external expenses under agreement                                               1,666   2,060 1,165        
IPH6101 agreement, with Sanofi                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Revenue from collaboration and licensing agreements                                               € 0   4,000 2,000        
Milestone payment received € 4,000                       € 2,000                                    
Agreements with Genzyme for NK Cell engages                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Milestone payment received                           € 25,000                                  
Advance received                           25,000                                  
Advance received - exclusive license                           18,500                                  
Advance received - research work                           1,500                                  
Advance received - additional targets                           5                                  
Milestone payment received - option exercised                           15,000                                  
Agreements with Sanofi for NK Cell engages                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Revenue from collaboration and licensing agreements | $                                                 $ 1,700            
Milestone payment received   € 15,000 € 2,000               € 7,000           € 3,000       € 4,000 € 3,000                  
Advance received             € 31,800                                                
Advance received - exclusive license             € 18,500             13,300                                  
Advance received - research work                           € 1,700                 $ 400   $ 400            
Number of exclusive options granted | option   2                       2                 2 2              
Number of options excercised for licenses | option   1                                                          
Milestone payment received - option exercised | $           $ 13,300                                                  
Termination notice period (in days)                                                         90 days    
Agreement with Takeda on research of Antibody Drug Conjugates (ADC)                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Initial payment       $ 5,000 € 4,600                                                    
Termination notice period (in days)                                                           90 days  
Agreement with Takeda on research of Antibody Drug Conjugates (ADC) | Collaboration liabilities                                                              
Disclosure of disaggregation of revenue from contracts with customers [line items]                                                              
Additions                                               € 0   € 0 € 8,200